Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

NF-kappa B Signaling-Related Signatures Are Connected with the Mesenchymal Phenotype of Circulating Tumor Cells in Non-Metastatic Breast Cancer.

Popeda M, Stokowy T, Bednarz-Knoll N, Jurek A, Niemira M, Bielska A, Kretowski A, Kalinowski L, Szade J, Markiewicz A, Zaczek AJ.

Cancers (Basel). 2019 Dec 6;11(12). pii: E1961. doi: 10.3390/cancers11121961.

2.

High-grade non-small cell lung carcinoma: a comparative analysis of the phenotypic profile in small biopsies with the corresponding postoperative material.

Szade J, Majewska HI, Żaczek AJ, Biernat W.

Pol J Pathol. 2019;70(2):100-108. doi: 10.5114/pjp.2019.84087.

3.

Low Numbers of Vascular Vessels Correlate to Progression in Hormone-Naïve Prostate Carcinomas Undergoing Radical Prostatectomy.

Smentoch J, Szade J, Żaczek AJ, Eltze E, Semjonow A, Brandt B, Bednarz-Knoll N.

Cancers (Basel). 2019 Sep 12;11(9). pii: E1356. doi: 10.3390/cancers11091356.

4.

Histoplasmosis in an elderly polish tourist - a case report.

Specjalski K, Kita K, Kuziemski K, Tokarska B, Górska L, Szade J, Siemińska A, Chełmińska M, Jassem E.

BMC Pulm Med. 2019 Aug 14;19(1):150. doi: 10.1186/s12890-019-0914-7.

5.

Clinical and Biological Significance of ESR1 Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients.

Nagel A, Szade J, Iliszko M, Elzanowska J, Welnicka-Jaskiewicz M, Skokowski J, Stasilojc G, Bigda J, Sadej R, Zaczek A, Markiewicz A.

Int J Mol Sci. 2019 Apr 16;20(8). pii: E1881. doi: 10.3390/ijms20081881.

6.

Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients.

Markiewicz A, Nagel A, Szade J, Majewska H, Skokowski J, Seroczynska B, Stokowy T, Welnicka-Jaskiewicz M, Zaczek AJ.

Transl Oncol. 2018 Jun;11(3):722-731. doi: 10.1016/j.tranon.2018.03.006. Epub 2018 Apr 16.

7.

Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation.

Senkus E, Szade J, Pieczyńska B, Kunc M, Pliszka A, Jassem J.

Histol Histopathol. 2018 Jan;33(1):55-64. doi: 10.14670/HH-11-887. Epub 2017 Mar 9.

PMID:
28276034
8.

Is histopathological diagnosis useful in choosing treatments for tumors of the temporal bone?

Kuczkowski J, Brzoznowski W, Szade J.

Am J Otolaryngol. 2017 May - Jun;38(3):367-368. doi: 10.1016/j.amjoto.2017.02.002. Epub 2017 Feb 13. No abstract available.

PMID:
28233583
9.

Symptoms mimicking Sjögren syndrome in a heterozygous carrier of CFTR deltaF508 mutation.

Domżalska M, Zdrojewski Z, Buda N, Masiak A, Szade J, Romanowicz G.

Pol Arch Med Wewn. 2016 Nov 28;126(11):895-896. doi: 10.20452/pamw.3654. Epub 2016 Nov 28. No abstract available.

10.

CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma.

Czapiewski P, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Sejda A, Szade J, Wiewiora C, Biernat W, Żaczek A.

Pol J Pathol. 2015 Sep;66(3):269-75.

11.

Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression.

Bednarz-Knoll N, Nastały P, Żaczek A, Stoupiec MG, Riethdorf S, Wikman H, Müller V, Skokowski J, Szade J, Sejda A, Wełnicka-Jaśkiewicz M, Pantel K.

Oncotarget. 2015 Sep 29;6(29):26789-803. doi: 10.18632/oncotarget.4628.

12.

Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation.

Markiewicz A, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Majewska H, Szade J, Żaczek AJ.

Am J Transl Res. 2014 Nov 22;6(6):793-808. eCollection 2014.

13.

Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair-matched immunohistochemical analysis aimed at intrinsic tumor phenotype.

Senkus E, Szade J, Pieczyńska B, Zaczek A, Świerblewski M, Biernat W, Jassem J.

Pathol Int. 2014 Oct;64(10):508-17. doi: 10.1111/pin.12202. Epub 2014 Oct 9.

PMID:
25296577
14.

Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential.

Markiewicz A, Książkiewicz M, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Szade J, Żaczek AJ.

PLoS One. 2014 Apr 7;9(4):e93901. doi: 10.1371/journal.pone.0093901. eCollection 2014.

15.

Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

Senkus E, Szade J, Pieczyńska B, Zaczek A, Pikiel J, Sosińska-Mielcarek K, Karpińska A, Jassem J.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):353-63. eCollection 2014.

16.

Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer.

Markiewicz A, Książkiewicz M, Seroczyńska B, Skokowski J, Szade J, Wełnicka-Jaśkiewicz M, Zaczek AJ.

Cancers (Basel). 2013 Nov 8;5(4):1485-503. doi: 10.3390/cancers5041485.

17.

Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.

Markiewicz A, Wełnicka-Jaśkiewicz M, Skokowski J, Jaśkiewicz J, Szade J, Jassem J, Zaczek AJ.

PLoS One. 2013 Aug 8;8(8):e72219. doi: 10.1371/journal.pone.0072219. eCollection 2013.

18.

Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

Senkus E, Szade J, Pieczyńska B, Żaczek A, Brożek I, Radecka B, Kowalczyk A, Wełnicka-Jaśkiewicz M, Jassem J.

Breast. 2013 Aug;22(4):425-30. doi: 10.1016/j.breast.2013.04.005. Epub 2013 May 1.

PMID:
23642527
19.

Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer.

Markiewicz A, Ahrends T, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Jaśkiewicz J, Szade J, Biernat W, Zaczek AJ.

J Transl Med. 2012 Nov 19;10:226. doi: 10.1186/1479-5876-10-226.

20.

Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.

Zaczek AJ, Markiewicz A, Seroczynska B, Skokowski J, Jaskiewicz J, Pienkowski T, Olszewski WP, Szade J, Rhone P, Welnicka-Jaskiewicz M, Jassem J.

Oncologist. 2012;17(10):1246-55. doi: 10.1634/theoncologist.2012-0023. Epub 2012 Aug 7.

Supplemental Content

Loading ...
Support Center